THCV and Metabolic Health: A Targeted Approach to Appetite, Energy and Weight Regulation

This webinar explores the emerging role of tetrahydrocannabivarin (THCV) in metabolic health, appetite regulation, and reducing THC-related daytime impairment. Participants will examine how THCV differs from THC, its potential applications in obesity, insulin resistance, and metabolic syndrome, and how nutrition, lifestyle interventions, and cannabinoid prescribing strategies can be integrated to support improved patient outcomes.

Webinar

When: Thursday 27 August 2026

Time: 7:00 pm

Cost: Free

Registration is free. You'll create a free My Medihuanna account to access the webinar, with no payment or subscription required.

By registering for this webinar, you consent to receiving communications from Medihuanna and our sponsors related to this event.

About the webinar

Tetrahydrocannabivarin (THCV) is an emerging cannabinoid attracting interest for its potential role in appetite regulation, metabolic health, and reducing THC-related daytime impairment. Unlike THC, which is commonly associated with increased appetite and sedation, THCV exhibits unique pharmacological properties that may help support energy, function, and metabolic regulation in selected patients. This evidence-based webinar explores the pharmacology of THCV, its interaction with the endocannabinoid system, and the emerging research surrounding its potential applications in obesity, insulin resistance, metabolic syndrome, and THC-induced hyperphagia. Participants will examine how THCV differs from THC, review the current evidence, and discuss its potential role within a broader metabolic health strategy. The session will also highlight the importance of nutrition, lifestyle modification, and patient-centred care, providing practical guidance on patient selection, prescribing considerations, and monitoring strategies. Designed for healthcare professionals, this webinar offers a balanced and clinically relevant overview of THCV and its potential place in contemporary cannabinoid medicine.

Learning Outcomes

Describe the pharmacology of THCV and how it differs from THC in appetite, cognition, and energy regulation

Evaluate appropriate clinical use cases for THCV, including metabolic disorders, overeating, and THC-related adverse effects

Apply practical prescribing strategies to optimise cannabinoid therapy and reduce daytime intoxication and hyperphagia

Integrate nutrition and lifestyle interventions alongside THCV to support metabolic health outcomes

About the speaker

Nick Robertson is Director of New Product Development and Innovation at Organigram, one of Canada’s leading licensed cannabis producers. During his 10 years with the company, Nick has progressed in various roles to now leading the development of new cannabis products, delivery formats and consumer experiences. His work sits at the intersection of cannabinoid science, product development and commercial strategy, translating emerging research and technologies into practical, scalable products. Nick has been closely involved in Organigram’s exploration of minor cannabinoids, including THCV, and the development of novel formulations designed to address evolving patient and consumer needs.

Our Sponsors

Claim 1 CPD Hour

Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 1659842). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.